SARS-CoV-2 Antibody Rapid Tests: Valuable Epidemiological Tools in Challenging Settings

Saluzzo, Francesca; Mantegani, Paola; Chaurand, Valeria Poletti de; Quaresima, Virginia; Cugnata, Federica; Serio, Clelia Di; Macé, Aurélien; Vos, Margaretha de; Sacks, Jilian A.; Cirillo, Daniela María

doi:10.1128/spectrum.00250-21

Cited by 8 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Binomial mixed model analysis found that the test results were not significantly impacted by day of sample collection (Day 21 or 42 post vaccine dose) which is consistent with findings indicating IgG antibodies are detectable between 21 and 60 days after vaccination (21,22). Similarly, vaccine brand did not significantly impact test results, both these findings highlight that wider testing could be flexible without compromising sensitivity.…”

Section: Discussionsupporting

confidence: 77%

Evaluation of Eight Lateral Flow Tests for the detection of anti-SARS-CoV-2 antibodies in a vaccinated population

Greenland-Bews

Byrne

Owen

et al. 2022

Preprint

View full text Add to dashboard Cite

With the distribution of COVID-19 vaccinations across the globe and the limited access in many countries, quick determination of an individual’s antibody status could be beneficial in allocating limited vaccine doses in low- and middle-income countries (LMIC). Antibody lateral flow tests (LFTs) have potential to address this need as a quick, point of care test, they also have a use case for identifying sero-negative individuals for novel therapeutics, and for epidemiology. Here we present a proof-of-concept evaluation of eight LFT brands using sera from 95 vaccinated individuals to determine sensitivity for detecting vaccination generated antibodies. All 95 (100%) participants tested positive for anti-spike antibodies by the chemiluminescent microparticle immunoassay (CMIA) reference standard post-dose two of their SARS-CoV-2 vaccine: BNT162b2 (Pfizer/BioNTech, n=60), AZD1222 (AstraZeneca, n=31), mRNA-1273 (Moderna, n=2) and Undeclared Vaccine Brand (n=2). Sensitivity increased from dose one to dose two in six out of eight LFTs with three tests achieving 100% sensitivity at dose two in detecting anti-spike antibodies. These tests are quick, low-cost point-of-care tools that can be used without prior training to establish antibody status and may prove valuable for allocating limited vaccine doses in LMICs to ensure those in at risk groups access the protection they need. Further investigation into their performance in vaccinated peoples is required before more widespread utilisation is considered.

show abstract

Section: Discussionsupporting

confidence: 77%

Evaluation of Eight Lateral Flow Tests for the detection of anti-SARS-CoV-2 antibodies in a vaccinated population

Greenland-Bews

Byrne

Owen

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Binomial mixed model analysis found that the test results were not significantly impacted by day of sample collection (Day 21 or 42 post vaccine dose) which is consistent with findings indicating IgG antibodies are detectable between 21 and 60 days after vaccination [22,23]. Similarly, vaccine brand did not significantly impact test results, both these findings highlight that wider testing could be flexible without compromising sensitivity.…”

Section: Discussionsupporting

confidence: 76%

Evaluation of eight lateral flow tests for the detection of anti-SARS-CoV-2 antibodies in a vaccinated population

et al. 2023

View full text Add to dashboard Cite

Background Rapid determination of an individual’s antibody status can be beneficial in understanding an individual’s immune response to SARS-CoV-2 and for initiation of therapies that are only deemed effective in sero-negative individuals. Antibody lateral flow tests (LFTs) have potential to address this need as a rapid, point of care test. Methods Here we present a proof-of-concept evaluation of eight LFT brands using sera from 95 vaccinated individuals to determine sensitivity for detecting vaccination generated antibodies. Samples were analysed on eight different brands of antibody LFT and an automated chemiluminescent microparticle immunoassay (CMIA) that identifies anti-spike antibodies which was used as our reference standard. Results All 95 (100%) participants tested positive for anti-spike antibodies by the chemiluminescent microparticle immunoassay (CMIA) reference standard post-dose two of their SARS-CoV-2 vaccine: BNT162b2 (Pfizer/BioNTech, n = 60), AZD1222 (AstraZeneca, n = 31), mRNA-1273 (Moderna, n = 2) and Undeclared Vaccine Brand (n = 2). Sensitivity increased from dose one to dose two in six out of eight LFTs with three tests achieving 100% sensitivity at dose two in detecting anti-spike antibodies. Conclusions These tests are demonstrated to be highly sensitive to detect raised antibody levels in vaccinated individuals. RDTs are low cost and rapid alternatives to ELISA based systems.

show abstract

“…There was low agreement of the SARS-CoV-2 Rapid Antibody Test (IgM) with the Elecsys Anti-SARS-CoV-2 S assay because, in general, there is a lower sensitivity for IgM compared with IgG for point-of-care lateral flow assays, as exemplified in a recent analysis of healthcare workers vaccinated with the first dose of the Pfizer vaccine and sampled 21–24 days thereafter ( 37 ). In addition, the Elecsys Anti-SARS-CoV-2 S assay preferentially detects high-affinity IgG antibodies that compete with IgM antibodies ( 23 ), contributing to the lower agreement rates with IgM results.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in Samples from Vaccinated Individuals

Hayer

Urlaub

2022

Microbiol Spectr

View full text Add to dashboard Cite

show abstract

SARS-CoV-2 Antibody Rapid Tests: Valuable Epidemiological Tools in Challenging Settings

Cited by 8 publications

References 17 publications

Evaluation of Eight Lateral Flow Tests for the detection of anti-SARS-CoV-2 antibodies in a vaccinated population

Evaluation of Eight Lateral Flow Tests for the detection of anti-SARS-CoV-2 antibodies in a vaccinated population

Evaluation of eight lateral flow tests for the detection of anti-SARS-CoV-2 antibodies in a vaccinated population

Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in Samples from Vaccinated Individuals

Contact Info

Product

Resources

About